logo

Cellectar Biosciences Inc (CLRB)



Trade CLRB now with
  Date
  Headline
10/30/2017 8:40:32 AM Cellectar Says Preclinical Data Suggest PDC Platform Provides Enhanced Outcomes In Combination With External Radiation
10/17/2017 8:33:30 AM Cellectar Biosciences Receives Additional Japanese Patent For CLR 131 And CLR 125 For Various Solid Tumors
9/21/2017 8:32:33 AM Cellectar Biosciences Enters Into Collaboration With Onconova Therapeutics To Develop New Phospholipid Drug Conjugates
8/1/2017 8:32:12 AM Cellectar Biosciences Signs Collaboration With Avicenna Oncology To Develop New PDCs For Solid Tumors
4/25/2017 8:40:41 AM Cellectar Biosciences Gets Addl. U.S. Patents For PDC Optical Agents In Detection Of Multiple Cancers
4/10/2017 4:06:41 PM Cellectar Biosciences Appoints Douglas Swirsky And Frederick Driscoll To Its Board Of Directors
2/27/2017 8:11:11 AM Cellectar Biosciences Provides An Update Of Its Phase I Clinical Study Of CLR 131
12/20/2016 8:41:09 AM Cellectar Biosciences Announces US And Japanese Patent Allowances For Diagnostic And Optical Imaging PDCs
12/14/2016 8:35:52 AM Cellectar Biosciences Unveils USPTO Grants Patent Allowances For Radiotherapeutic PDCs For Variety Of Solid Tumor Types
12/1/2016 8:05:52 AM Cellectar Biosciences Announces Results From The First Two Cohorts Of Its CLR 131 Phase 1 Trial
11/28/2016 8:21:43 AM Cellectar Biosciences Selects Hamilton, Ontario-based Centre For Probe Development And Commercialization
11/23/2016 8:32:11 AM Cellectar Biosciences Announces Pricing Of $8 Mln Public Offering
10/31/2016 9:45:56 AM Cellectar Announces Design For NCI-Supported Phase II Study Of CLR 131 In MM And Other Hematologic Malignancies
10/24/2016 8:33:36 AM Cellectar Biosciences Announces Data On CLR 131 Accepted For Poster Presentation
10/6/2016 8:43:31 AM Cellectar Biosciences Enrolls First Patient Into Cohort 3 Of Phase I Clinical Study Of CLR 131
10/4/2016 8:36:40 AM Cellectar Biosciences: USPTO Issues Formal Patent Allowance For CLR 1603
  
 
>